227 related articles for article (PubMed ID: 32504084)
1. Overexpression of Staufen1 in DM1 mouse skeletal muscle exacerbates dystrophic and atrophic features.
Crawford Parks TE; Marcellus KA; Péladeau C; Jasmin BJ; Ravel-Chapuis A
Hum Mol Genet; 2020 Aug; 29(13):2185-2199. PubMed ID: 32504084
[TBL] [Abstract][Full Text] [Related]
2. The RNA-binding protein Staufen1 is increased in DM1 skeletal muscle and promotes alternative pre-mRNA splicing.
Ravel-Chapuis A; Bélanger G; Yadava RS; Mahadevan MS; DesGroseillers L; Côté J; Jasmin BJ
J Cell Biol; 2012 Mar; 196(6):699-712. PubMed ID: 22431750
[TBL] [Abstract][Full Text] [Related]
3. Staufen1 Regulates Multiple Alternative Splicing Events either Positively or Negatively in DM1 Indicating Its Role as a Disease Modifier.
Bondy-Chorney E; Crawford Parks TE; Ravel-Chapuis A; Klinck R; Rocheleau L; Pelchat M; Chabot B; Jasmin BJ; Côté J
PLoS Genet; 2016 Jan; 12(1):e1005827. PubMed ID: 26824521
[TBL] [Abstract][Full Text] [Related]
4. Muscle-specific expression of the RNA-binding protein Staufen1 induces progressive skeletal muscle atrophy via regulation of phosphatase tensin homolog.
Crawford Parks TE; Ravel-Chapuis A; Bondy-Chorney E; Renaud JM; Côté J; Jasmin BJ
Hum Mol Genet; 2017 May; 26(10):1821-1838. PubMed ID: 28369467
[TBL] [Abstract][Full Text] [Related]
5. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1.
Ward AJ; Rimer M; Killian JM; Dowling JJ; Cooper TA
Hum Mol Genet; 2010 Sep; 19(18):3614-22. PubMed ID: 20603324
[TBL] [Abstract][Full Text] [Related]
6. Vorinostat Improves Myotonic Dystrophy Type 1 Splicing Abnormalities in DM1 Muscle Cell Lines and Skeletal Muscle from a DM1 Mouse Model.
Neault N; Ravel-Chapuis A; Baird SD; Lunde JA; Poirier M; Staykov E; Plaza-Diaz J; Medina G; Abadía-Molina F; Jasmin BJ; MacKenzie AE
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835205
[TBL] [Abstract][Full Text] [Related]
7. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
[TBL] [Abstract][Full Text] [Related]
8. Chronic exercise mitigates disease mechanisms and improves muscle function in myotonic dystrophy type 1 mice.
Manta A; Stouth DW; Xhuti D; Chi L; Rebalka IA; Kalmar JM; Hawke TJ; Ljubicic V
J Physiol; 2019 Mar; 597(5):1361-1381. PubMed ID: 30628727
[TBL] [Abstract][Full Text] [Related]
9. Gain of RNA function in pathological cases: Focus on myotonic dystrophy.
Klein AF; Gasnier E; Furling D
Biochimie; 2011 Nov; 93(11):2006-12. PubMed ID: 21763392
[TBL] [Abstract][Full Text] [Related]
10. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1.
de Haro M; Al-Ramahi I; De Gouyon B; Ukani L; Rosa A; Faustino NA; Ashizawa T; Cooper TA; Botas J
Hum Mol Genet; 2006 Jul; 15(13):2138-45. PubMed ID: 16723374
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and physiological activation of AMPK improves the spliceopathy in DM1 mouse muscles.
Ravel-Chapuis A; Al-Rewashdy A; Bélanger G; Jasmin BJ
Hum Mol Genet; 2018 Oct; 27(19):3361-3376. PubMed ID: 29982462
[TBL] [Abstract][Full Text] [Related]
12. Age of onset of RNA toxicity influences phenotypic severity: evidence from an inducible mouse model of myotonic dystrophy (DM1).
Gladman JT; Mandal M; Srinivasan V; Mahadevan MS
PLoS One; 2013; 8(9):e72907. PubMed ID: 24039817
[TBL] [Abstract][Full Text] [Related]
13. Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy.
Leger AJ; Mosquea LM; Clayton NP; Wu IH; Weeden T; Nelson CA; Phillips L; Roberts E; Piepenhagen PA; Cheng SH; Wentworth BM
Nucleic Acid Ther; 2013 Apr; 23(2):109-17. PubMed ID: 23308382
[TBL] [Abstract][Full Text] [Related]
14. Misregulation of calcium-handling proteins promotes hyperactivation of calcineurin-NFAT signaling in skeletal muscle of DM1 mice.
Ravel-Chapuis A; Bélanger G; Côté J; Michel RN; Jasmin BJ
Hum Mol Genet; 2017 Jun; 26(12):2192-2206. PubMed ID: 28369518
[TBL] [Abstract][Full Text] [Related]
15. Furamidine Rescues Myotonic Dystrophy Type I Associated Mis-Splicing through Multiple Mechanisms.
Jenquin JR; Coonrod LA; Silverglate QA; Pellitier NA; Hale MA; Xia G; Nakamori M; Berglund JA
ACS Chem Biol; 2018 Sep; 13(9):2708-2718. PubMed ID: 30118588
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1.
Morriss GR; Rajapakshe K; Huang S; Coarfa C; Cooper TA
Hum Mol Genet; 2018 Aug; 27(16):2789-2804. PubMed ID: 29771332
[TBL] [Abstract][Full Text] [Related]
17. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing.
Charlet-B N; Savkur RS; Singh G; Philips AV; Grice EA; Cooper TA
Mol Cell; 2002 Jul; 10(1):45-53. PubMed ID: 12150906
[TBL] [Abstract][Full Text] [Related]
18. Staufen1 impairs stress granule formation in skeletal muscle cells from myotonic dystrophy type 1 patients.
Ravel-Chapuis A; Klein Gunnewiek A; Bélanger G; Crawford Parks TE; Côté J; Jasmin BJ
Mol Biol Cell; 2016 Jun; 27(11):1728-39. PubMed ID: 27030674
[TBL] [Abstract][Full Text] [Related]
19. Aberrantly spliced alpha-dystrobrevin alters alpha-syntrophin binding in myotonic dystrophy type 1.
Nakamori M; Kimura T; Kubota T; Matsumura T; Sumi H; Fujimura H; Takahashi MP; Sakoda S
Neurology; 2008 Feb; 70(9):677-85. PubMed ID: 18299519
[TBL] [Abstract][Full Text] [Related]
20. In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
González ÀL; Konieczny P; Llamusi B; Delgado-Pinar E; Borrell JI; Teixidó J; García-España E; Pérez-Alonso M; Estrada-Tejedor R; Artero R
PLoS One; 2017; 12(6):e0178931. PubMed ID: 28582438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
